Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31523429 | 0.89 | MAP3K14 (0.41) | MAP3K14GPR119HDAC1HDAC6HPGDS | |
| SCHEMBL31523349 | 0.89 | MAP3K14 (0.39) | MAP3K14GPR119HDAC1HDAC6HPGDS | |
| SCHEMBL31523418 | 0.88 | MAP3K14 (0.39) | MAP3K14GPR119HDAC1HDAC6HPGDS | |
| SCHEMBL31523062 | 0.88 | HDAC1 (0.40) | MAP3K14HDAC1HDAC6HPGDSMKNK1 | |
| SCHEMBL31522854 | 0.87 | HDAC1 (0.39) | MAP3K14HDAC1HDAC6HPGDSMKNK1 | |
| SCHEMBL31523622 | 0.84 | MAP3K14 (0.41) | MAP3K14GPR119HDAC1HDAC6ESR2 | |
| SCHEMBL31523491 | 0.82 | RET (0.42) | MAP3K14GPR119HPGDSDDB1CRBN | |
| SCHEMBL31522846 | 0.81 | LMNA (0.43) | MAP3K14GPR119HDAC1HDAC6HPGDS | |
| SCHEMBL31523566 | 0.78 | MKNK1 (0.42) | MAP3K14HDAC1HDAC6HPGDSMKNK1 | |
| SCHEMBL31522890 | 0.77 | MKNK1 (0.41) | MAP3K14HDAC1HDAC6HPGDSMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| WO-2025054488-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | MAP3K14 3293/4885GPR119 3785/4885HDAC1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.